Schrödinger, Inc. (SDGR)
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For Free
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-making in clinical trials. Schrödinger has attracted substantial investment from strategic partnerships and has a diverse pipeline of drug candidates in clinical development.
1 Growth Stock That Could Dominate AI's Next Breakthrough
Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below.
